Delta-radiomics plus clinical model predicts survival in high-grade glioma after chemoradiotherapy

Delta-radiomics plus clinical variables predicted overall survival in high-grade glioma after chemoradiotherapy: C-index 0.818 internal validation, 0.761 external test, outperforming radiomics or clinical alone.

• Retrospective study of 143 patients with high-grade glioma from two centers; training cohort 116 (5-fold cross-validation), external test cohort 27.
• Time-dependent AUCs in external test for 12-, 18-, 24-, and 30-month overall survival were 0.842, 0.856, 0.796, and 0.943; Kaplan-Meier risk stratification p=0.002.
• Limitation stated by authors: small external validation cohort and absence of MGMT promoter methylation status from main model; exploratory findings require larger prospective validation.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.